Liquidia (NASDAQ:LQDA) CAO Sells $643,733.02 in Stock

Liquidia Corporation (NASDAQ:LQDA) CAO Dana Boyle sold 9,002 shares of the firm’s stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $71.51, for a total value of $643,733.02. Following the completion of the sale, the chief accounting officer directly owned 169,519 shares in the company, valued at $12,122,303.69. This trade represents a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dana Boyle also recently made the following trade(s):

• On Monday, April 27th, Dana Boyle sold 1,576 shares of Liquidia stock. The shares were sold at an average price of $37.78, for a total value of $59,541.28.

Liquidia Stock Down 3.2%

Shares of NASDAQ LQDA opened at $75.27 on Friday. The company has a market cap of $6.69 billion, a price-to-earnings ratio of 537.68 and a beta of 0.55. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 12 month low of $14.04 and a 12 month high of $82.96. The stock has a 50-day moving average price of $67.74 and a two-hundred day moving average price of $48.10.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. Liquidia’s revenue was up 4187.1% on a year-over-year basis. As a group, analysts forecast that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Liquidia

Hedge funds have recently modified their holdings of the business. Handelsbanken Fonder AB bought a new stake in shares of Liquidia in the second quarter worth $1,993,000. Fulcrum Equity Management bought a new position in Liquidia during the 2nd quarter worth $399,000. Fluent Financial LLC bought a new position in Liquidia during the 2nd quarter worth $287,000. FNY Investment Advisers LLC acquired a new position in Liquidia during the 2nd quarter worth about $1,395,000. Finally, Seven Fleet Capital Management LP lifted its holdings in Liquidia by 124.5% during the 1st quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock worth $7,732,000 after buying an additional 113,609 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Bank of America reiterated a “neutral” rating and set a $79.00 price target (up from $64.00) on shares of Liquidia in a report on Monday, June 29th. Needham & Company LLC increased their price target on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, May 11th. HC Wainwright raised their price objective on Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a report on Friday, June 5th. Finally, Wells Fargo & Company boosted their price objective on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Three research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Liquidia presently has an average rating of “Moderate Buy” and a consensus price target of $68.88.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).